US Edition
News from biopharmadive.com
Media Bias Ratings
Average Bias Rating:
Center
Center
byMedia Bias/Fact CheckDo you disagree?
Edit bias
Learn more about Media Bias Ratings.
Factuality
Learn more about Factuality Ratings
Reveal Factuality Ratings by upgrading to a Premium account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Ownership
Learn more about Ownership categories
Reveal Ownership Data by upgrading to a Vantage account.
Tap Upgrade to explore subscription options to meet all your reading needs.
Top biopharmadive.com News
Vaccines · United StatesHealth and Human Services Secretary Robert F. Kennedy Jr.'s influential vaccine advisory panel on Thursday delayed a vote for a second time on whether to change the timing of the first dose of the hepatitis B vaccine for newborns.
See the Story
RFK Jr.’s vaccine panel defers vote on hepatitis B shot for babies until Friday
55% Center coverage: 47 sources
FDA · United StatesA dozen prior leaders of the U.S. Food and Drug Administration — appointed by Republicans and Democrats alike — issued a scathing denunciation of new FDA assertions casting doubt on vaccine safety.See the Story
A dozen former FDA leaders lambaste claims by the agency’s current vaccine chief
57% Center coverage: 42 sources
PharmaRetatrutide, the next generation of GLP-1 drug from Eli Lilly, helped participants lose an average of 71.2 pounds and reduce knee arthritis pain in a late-stage clinical trial, the company announced.In fact, some of the participants dropped out of the trial because they were losing too much weight, the pharmaceutical company said.Retatrutide is an experimental triple agonist medication, mimicking three different gut hormones in the body GLP-1, G…See the Story
Eli Lilly's Next-Gen Obesity Drug Shows Biggest Weight Loss yet in Clinical Trial
62% Center coverage: 24 sources
